B7777

Budesonide

≥99%

• 동의어(들): 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
• 실험식(Hill 표기법): C₂₅H₃₄O₆
• CAS Number: 51333-22-3
• Molecular Weight: 430.53
• EC Number: 257-139-7
• MDL number: MFCD00083259
• UNSPSC 코드: 12352200
• PubChem Substance ID: 24278277
• NACRES: NA.77

속성

• Quality Level: 200
• 분석: ≥99%
• 형태: powder
• 주관자: AstraZeneca
• SMILES string: [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO
• InChI: 1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
• InChI key: VOVIALXJUBGFJZ-KWVAZRHASA-N
• 유전자 정보: human ... IFNG(3458) , IL5(3567) , NR3C1(2908) ; rat ... Nr3c1(24413)

설명

생화학적/생리학적 작용

Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice.

특징 및 장점

This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

안전성 정보

• 픽토그램: GHS08,GHS07
• 신호어: Danger
• 유해 및 위험 성명서: H302,H317,H361d,H372,H412
• 예방조치 성명서: P202 - P273 - P280 - P301 + P312 - P302 + P352 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Chronic 3 - Repr. 2 - Skin Sens. 1 - STOT RE 1 Inhalation
• 표적 기관: Adrenal gland
• Storage Class Code: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• WGK: WGK 3
• Flash Point (°F): Not applicable
• Flash Point (°C): Not applicable
• 개인 보호 장비: Eyeshields, Gloves, type N95 (US)